Literature DB >> 6723490

Distribution of phenobarbital in serum, brain and other organs from pediatric patients.

S Onishi, Y Ohki, Y Nishimura, S Itoh, K Isobe, A Hosoe, T Yamamoto, T Yamakawa.   

Abstract

The present study was performed to determine whether serum levels of phenobarbital were representative of their concentrations in the brains obtained from 11 autopsied patients, including premature and full-term babies, infants and children. Estimation of phenobarbital concentrations in plasma and organs was performed by high-pressure liquid chromatography. Brain phenobarbital concentrations correlated well with serum levels (r = 0.82, p less than 0.01, n = 11), giving a regression line with a slope of 0.75. It can be concluded that estimating the serum phenobarbital concentration during clinical pediatric practice gives a good indication of the brain concentration.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6723490     DOI: 10.1159/000457158

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  5 in total

Review 1.  Pharmacokinetic considerations in the treatment of childhood epilepsy.

Authors:  Jamie T Gilman; Michael Duchowny; Ana E Campo
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

2.  Pharmacokinetic and pharmacodynamic data collection in children and neonates. A quiet frontier.

Authors:  J T Gilman; P Gal
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

Review 3.  Therapeutic drug monitoring in the neonate and paediatric age group. Problems and clinical pharmacokinetic implications.

Authors:  J T Gilman
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

Review 4.  Pharmacokinetic variability of phenobarbital: a systematic review of population pharmacokinetic analysis.

Authors:  Janthima Methaneethorn; Nattawut Leelakanok
Journal:  Eur J Clin Pharmacol       Date:  2020-10-19       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.